| . | . | Before Treatment At Baseline . | After Treatment At Surgery . | ||
|---|---|---|---|---|---|
| Hormonal safety . | . | Placebo N = 85 . | Promestriene N = 84 . | Placebo N = 85 . | Promestriene N = 84 . |
| LH (UI/L) | Mean (+/- SD) | 0.07 (±0.07) | 0.07 (±0.06) | 0.46 (±0.40) | 0.49 (±0.44) |
| FSH (UI/L) | Mean (+/- SD) | 0.33 (±0.27) | 0.34 (±0.31) | 0.61 (±0.40) | 0.53 (±0.41) |
| AMH (pmol/L) | Mean (±SD) | 1689 (±771) | 1703 (±758) | 1362 (±691) | 1511 (±717) |
| Estradiol (pmol/L) | Mean (±SD) | 1.33 (±8.17) | 2.63 (±8.48) | 1.91 (±9.20) | 2.40 (±8.09) |
| Bone age safety | Placebo N = 70 | Promestriene N = 67 | Placebo N = 70 | Promestriene N = 67 | |
| Estimated bone age (months) | Mean (±SD) | 14.8 (±8.65) | 12.8 (±9.6) | 31.0 (±8.9) | 30.1 (±10.6) |
| Effective age (months) | Mean (±SD) | 15.7(±5.2) | 15.8 (±5.1) | 30.4 (±5.3) | 30.7 (±5.7) |
| . | . | Before Treatment At Baseline . | After Treatment At Surgery . | ||
|---|---|---|---|---|---|
| Hormonal safety . | . | Placebo N = 85 . | Promestriene N = 84 . | Placebo N = 85 . | Promestriene N = 84 . |
| LH (UI/L) | Mean (+/- SD) | 0.07 (±0.07) | 0.07 (±0.06) | 0.46 (±0.40) | 0.49 (±0.44) |
| FSH (UI/L) | Mean (+/- SD) | 0.33 (±0.27) | 0.34 (±0.31) | 0.61 (±0.40) | 0.53 (±0.41) |
| AMH (pmol/L) | Mean (±SD) | 1689 (±771) | 1703 (±758) | 1362 (±691) | 1511 (±717) |
| Estradiol (pmol/L) | Mean (±SD) | 1.33 (±8.17) | 2.63 (±8.48) | 1.91 (±9.20) | 2.40 (±8.09) |
| Bone age safety | Placebo N = 70 | Promestriene N = 67 | Placebo N = 70 | Promestriene N = 67 | |
| Estimated bone age (months) | Mean (±SD) | 14.8 (±8.65) | 12.8 (±9.6) | 31.0 (±8.9) | 30.1 (±10.6) |
| Effective age (months) | Mean (±SD) | 15.7(±5.2) | 15.8 (±5.1) | 30.4 (±5.3) | 30.7 (±5.7) |
| . | . | Before Treatment At Baseline . | After Treatment At Surgery . | ||
|---|---|---|---|---|---|
| Hormonal safety . | . | Placebo N = 85 . | Promestriene N = 84 . | Placebo N = 85 . | Promestriene N = 84 . |
| LH (UI/L) | Mean (+/- SD) | 0.07 (±0.07) | 0.07 (±0.06) | 0.46 (±0.40) | 0.49 (±0.44) |
| FSH (UI/L) | Mean (+/- SD) | 0.33 (±0.27) | 0.34 (±0.31) | 0.61 (±0.40) | 0.53 (±0.41) |
| AMH (pmol/L) | Mean (±SD) | 1689 (±771) | 1703 (±758) | 1362 (±691) | 1511 (±717) |
| Estradiol (pmol/L) | Mean (±SD) | 1.33 (±8.17) | 2.63 (±8.48) | 1.91 (±9.20) | 2.40 (±8.09) |
| Bone age safety | Placebo N = 70 | Promestriene N = 67 | Placebo N = 70 | Promestriene N = 67 | |
| Estimated bone age (months) | Mean (±SD) | 14.8 (±8.65) | 12.8 (±9.6) | 31.0 (±8.9) | 30.1 (±10.6) |
| Effective age (months) | Mean (±SD) | 15.7(±5.2) | 15.8 (±5.1) | 30.4 (±5.3) | 30.7 (±5.7) |
| . | . | Before Treatment At Baseline . | After Treatment At Surgery . | ||
|---|---|---|---|---|---|
| Hormonal safety . | . | Placebo N = 85 . | Promestriene N = 84 . | Placebo N = 85 . | Promestriene N = 84 . |
| LH (UI/L) | Mean (+/- SD) | 0.07 (±0.07) | 0.07 (±0.06) | 0.46 (±0.40) | 0.49 (±0.44) |
| FSH (UI/L) | Mean (+/- SD) | 0.33 (±0.27) | 0.34 (±0.31) | 0.61 (±0.40) | 0.53 (±0.41) |
| AMH (pmol/L) | Mean (±SD) | 1689 (±771) | 1703 (±758) | 1362 (±691) | 1511 (±717) |
| Estradiol (pmol/L) | Mean (±SD) | 1.33 (±8.17) | 2.63 (±8.48) | 1.91 (±9.20) | 2.40 (±8.09) |
| Bone age safety | Placebo N = 70 | Promestriene N = 67 | Placebo N = 70 | Promestriene N = 67 | |
| Estimated bone age (months) | Mean (±SD) | 14.8 (±8.65) | 12.8 (±9.6) | 31.0 (±8.9) | 30.1 (±10.6) |
| Effective age (months) | Mean (±SD) | 15.7(±5.2) | 15.8 (±5.1) | 30.4 (±5.3) | 30.7 (±5.7) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
